



# Nevada PEBP

Q1 FY2025

Prepared by Client Analytics

Cynthia Eaton ([cynthia.eaton@express-scripts.com](mailto:cynthia.eaton@express-scripts.com))

11/30/24

*\*The data contained herein is pulled from a specific point-in-time and is subject to change at any time without notice due to a variety of factors, including but not limited to changes related to Member behavior, population demographics, system updates, and product availability. The data does not represent a guarantee and should not be used for audit purposes.*

Hello PEBP Team,

This is the Q1 FY25 Summary File for the three State of Nevada PEBP plans (CDHP, EPO, and PPO). The summary contains Trend breakouts for each plan (Utilization, Unit Cost, and Cost Share). Along with the most notable changes of drugs within the top moving indications. Each plan breakout has a peer comparison of Trend. The file concludes with several Key Statistics of the three plans in aggregate.

### **CDHP Overall Trend Summaries:**

<b>CDHP Overall Trend</b>		<b>% Change</b>
<b>Current Period - Plan Cost Net PMPM</b>	<b>\$68.18</b>	
Utilization	\$3.46	5.4%
Unit Cost	\$3.32	5.2%
Member Share	(\$3.02)	(4.7%)
<b>Total Change in Plan Cost Net PMPM</b>	<b>\$3.75</b>	<b>5.8%</b>
<b>Previous Period - Plan Cost Net PMPM</b>	<b>\$64.42</b>	

Top moving indications and most notable drug changes within the indications are as follows:

- **Cancer:** Previous ranked 1<sup>st</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$94k (11.5%) to current \$913k.
  - Plan Cost Net PMPM ↑ 2.16 \$ (19.2%) to current \$13.36.
  - Patient Count ↓ 4 to current count of 161.
  - Adjusted Rxs ↓ 25 to current count of 436.
- **Notable Drug Changes within Indication:**
  - **Brukinsa:**
    - Previous ranked 11<sup>th</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$56k (185.2%) to current \$87k.
    - Plan Cost Net PMPM ↑ \$.85 (205.1%) to current \$1.27.
    - Patient Count ↑ 1 to current count of 2.
    - Adjusted Rxs ↑ 3 to current count of 6.
  - **Nubeqa:**
    - New, currently ranked 3<sup>rd</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$86k.
    - Plan Cost Net PMPM: New, current \$1.26.
    - Patient Count: New, current count of 3.
    - Adjusted Rxs: New, current count of 10.

- **Cabometyx:**
  - New, currently ranked 5<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net: New, current \$74k.
  - Plan Cost Net PMPM: New, current \$1.09.
  - Patient Count: New, current count of 1.
  - Adjusted Rxs: New, current count of 3.
  
- **Inflammatory Conditions:** Previous ranked 1<sup>st</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
  - Plan Cost Net ↓ \$141k (-15.0%) to current \$795k.
  - Plan Cost Net PMPM ↓ \$1.17 (-9.1%) to current \$11.64.
  - Patient Count ↓ 9 to current count of 182.
  - Adjusted Rxs ↓ 11 to current count of 570.
  
- **Notable Drug Changes within Indication:**
  - **Humira (CF) Pen:**
    - Previous ranked 1<sup>st</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net ↓ \$171k (-63.0%) to current \$101k.
    - Plan Cost Net PMPM ↓ \$2.24 (-60.4%) to current \$1.47.
    - Patient Count ↓ 1 to current count of 24.
    - Adjusted Rxs ↓ 27 to current count of 46.
  
  - **Rinvoq:**
    - Previous ranked 5<sup>th</sup>, currently ranked 3<sup>rd</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$35k (77.7%) to current \$80k.
    - Plan Cost Net PMPM ↑ \$.56 (90.1%) to current \$1.18.
    - Patient Count ↑ 3 to current count of 8.
    - Adjusted Rxs ↑ 9 to current count of 23.
  
  - **Otezla:**
    - Previous ranked 7<sup>th</sup>, currently ranked 4<sup>th</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$25k (64.3%) to current \$65k.
    - Plan Cost Net PMPM ↑ \$.41 (75.7%) to current \$.95.
    - Patient Count: Remains at 14.
    - Adjusted Rxs ↑ 4 to current count of 39.
  
  - **Stelara:**
    - Previous ranked 3<sup>rd</sup>, currently ranked 5<sup>th</sup> by Plan Cost Net.
    - Plan Cost Net ↓ \$27k (-29.3%) to current \$64k.
    - Plan Cost Net PMPM ↓ \$.30 (-24.4%) to current \$.94.
    - Patient Count ↓ 1 to current count of 6.
    - Adjusted Rxs: Remains at 20.

- **Vaccinations:** Previous ranked 5<sup>th</sup>, currently ranked 4<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$85k (29.4%) to current \$373k.
  - Plan Cost Net PMPM ↑ \$1.51 (38.4%) to current \$5.45.
  - Patient Count ↓ 84 to current count of 1,750.
  - Adjusted Rxs ↑ 275 to current count of 3,079.
  
- **Notable Drug Changes within Indication:**
  - **Comirnaty (COVID) 2024-2025:** New, currently ranked 1<sup>st</sup>.
    - Plan Cost Net: New, current \$101k.
    - Plan Cost Net PMPM: New, current \$1.48.
    - Patient Count: New, current count of 610.
    - Adjusted Rxs: New, current count of 610.
  - **Spikevax (COVID) 2024-2025:** New, currently ranked 2<sup>nd</sup>.
    - Plan Cost Net: New, current \$69k.
    - Plan Cost Net PMPM: New, current \$1.00.
    - Patient Count: New, current count of 403.
    - Adjusted Rxs: New, current count of 403.
  - **Other drug changes in this indication were not notable.**
  
- **Blood Cell Deficiency:** Previous ranked 48<sup>th</sup>, currently ranked 9<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$178k (17,097.8%) to current \$179k.
  - Plan Cost Net PMPM ↑ \$2.61 (18,298.4%) to current \$2.62.
  - Patient Count ↑ 4 to current count of 5.
  - Adjusted Rxs ↑ 9 to current count of 12.
  
- **Notable Drug Changes within Indication:**
  - **Promacta:**
    - New, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$157k.
    - Plan Cost Net PMPM: New, current \$2.30.
    - Patient Count: New, current count of 1.
    - Adjusted Rxs: New, current count of 4.
  - **Doptelet:**
    - New, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$18k.
    - Plan Cost Net PMPM: New, current \$.27.
    - Patient Count: New, current count of 1.
    - Adjusted Rxs: New, current count of 3.
  - **Other drug changes in this indication were not notable.**

## Peer Comparison:

- Peer: ESI CDH Program
- PEBP CDHP is outperforming the peer.
- Peer experienced Plan Cost Net PMPM of \$97.87 compared to CDHP PEBP of \$68.18.
- Peer experienced Trend of 17.8%, compared to CDHP PEBP Trend of 5.8%

## EPO Overall Trend Summaries:

EPO Overall Trend		% Change
<b>Current Period - Plan Cost Net PMPM</b>	<b>\$191.29</b>	
Utilization	\$8.81	5.8%
Unit Cost	\$29.52	19.3%
Member Share	\$0.09	0.1%
<b>Total Change in Plan Cost Net PMPM</b>	<b>\$38.43</b>	<b>25.1%</b>

**Previous Period - Plan Cost Net PMPM** **\$152.86**

Top moving indications and most notable drug changes within the indications are as follows:

- **Cancer:** Previous ranked 4<sup>th</sup>, currently ranked 3<sup>rd</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$96k (42.4%) to current \$321k.
  - Plan Cost Net PMPM ↑ \$7.38 (57.2%) to current \$20.28.
  - Patient Count ↓ 5 to current count of 46.
  - Adjusted Rxs ↓ 4 to current count of 143.
- **Notable Drug Changes within Indication:**
  - **Erleada:**
    - New, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$49k.
    - Plan Cost Net PMPM: New, current \$3.10.
    - Patient Count: New, current count of 1.
    - Adjusted Rxs: New, current count of 4.
  - **Venclexta:**
    - Previous ranked 4<sup>th</sup>, currently ranked 4<sup>th</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$25k (123.4%) to current \$45k.
    - Plan Cost Net PMPM ↑ \$1.70 (146.6%) to current \$2.86.
    - Patient Count: Remains at 1.
    - Adjusted Rxs ↑ 1 to current count of 3.
  - **Koselugo:**
    - New, currently ranked 5<sup>th</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$45k.
    - Plan Cost Net PMPM: New, current \$2.85.

- Patient Count: New, current count of 1.
  - Adjusted Rxs: New, current count of 2.
- **Seizures:** Previous ranked 6<sup>th</sup>, currently ranked 4<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$82k (92.2%) to current \$171k.
  - Plan Cost Net PMPM ↑ \$5.71 (112.3%) to current \$10.80.
  - Patient Count ↓ 16 to current count of 167.
  - Adjusted Rxs ↓ 15 to current count of 576.
- **Notable Drug Changes within Indication:**
  - **Fintepla:**
    - Previous ranked 1<sup>st</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$75k (133.4%) to current \$132k.
    - Plan Cost Net PMPM ↑ \$5.11 (157.7%) to current \$8.34.
    - Patient Count ↑ 1 to current count of 2.
    - Adjusted Rxs ↑ 4 to current count of 7.
  - **Other drug changes in this indication were not notable.**
- **Endocrine Disorders:** Previous ranked 2<sup>nd</sup>, currently ranked 5<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↓ \$243k (-60.5%) to current \$159k.
  - Plan Cost Net PMPM ↓ \$12.95 (-56.3%) to current \$10.03.
  - Patient Count ↑ 3 to current count of 23.
  - Adjusted Rxs ↑ 15 to current count of 68.
- **Notable Drug Changes within Indication:**
  - **Korlym:**
    - Previous ranked 1<sup>st</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net ↓ \$306k (-79.3%) to current \$80k.
    - Plan Cost Net PMPM ↓ \$17.02 (-77.1%) to current \$5.06.
    - Patient Count: Remains at 2.
    - Adjusted Rxs ↓ 5 to current count of 2.
  - **Supprelin LA:**
    - New, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$49k.
    - Plan Cost Net PMPM: New, current \$3.07.
    - Patient Count: New, current count of 1.
    - Adjusted Rxs: New, current count of 12.
  - **Other drug changes in this indication were not notable.**

- **Gout:** Previous ranked 39<sup>th</sup>, currently ranked 6<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$123k (2,478.8%) to current \$128k.
  - Plan Cost Net PMPM ↑ \$7.78 (2,747.7%) to current \$8.06.
  - Patient Count ↑ 1 to current count of 90.
  - Adjusted Rxs ↓ 38 to current count of 239.
  
- **Notable Drug Changes within Indication:**
  - **Krystexxa:**
    - New, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$124k.
    - Plan Cost Net PMPM: New, current \$7.85.
    - Patient Count: New, current count of 2.
    - Adjusted Rxs: New, current count of 3.
  
  - **Other drug changes in this indication were not notable.**

**Peer Comparison:**

- Government – West Region/SaveOn (custom peer created for PEBP EPO plan)
- The peer is outperforming PEBP EPO.
- Peer experienced Plan Cost Net PMPM of \$126.34 compared to PEBP EPO of \$191.29.
- Peer experienced Trend of 24.1%, compared to PEBP EPO of 25.1%.

**PPO Overall Trend Summaries:**

PPO Overall Trend	% Change	
<b>Current Period - Plan Cost Net PMPM</b>	<b>\$102.23</b>	
Utilization	\$5.94	6.7%
Unit Cost	\$8.03	9.1%
Member Share	(\$0.34)	(0.4%)
<b>Total Change in Plan Cost Net PMPM</b>	<b>\$13.63</b>	<b>15.4%</b>
<b>Previous Period - Plan Cost Net PMPM</b>	<b>\$88.60</b>	

Top moving indications and most notable drug changes within the indications are as follows:

- **Diabetes:** Previous ranked 2<sup>nd</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$316k (51.9%) to current \$926k.
  - Plan Cost Net PMPM ↑ \$2.46 (22.1%) to current \$13.59.
  - Patient Count ↑ 424 to current count of 1,439.
  - Adjusted Rxs ↑ 2,066 to current count of 7,546.

- **Notable Drug Changes within Indication:**
  - **Mounjaro:**
    - Previous ranked 2<sup>nd</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$179k (161.0%) to current \$291k.
    - Plan Cost Net PMPM ↑ \$2.23 (109.9%) to current \$4.27.
    - Patient Count ↑ 152 to current count of 255.
    - Adjusted Rxs ↑ 509 to current count of 823.
  - **Ozempic:**
    - Previous ranked 1<sup>st</sup>, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$83k (44.1%) to current \$271k.
    - Plan Cost Net PMPM ↑ \$.55 (15.9%) to current \$3.98.
    - Patient Count ↑ 104 to current count of 299.
    - Adjusted Rxs ↑ 305 to current count of 884.
  - **Trulicity:**
    - Previous ranked 3<sup>rd</sup>, currently ranked 3<sup>rd</sup> by Plan Cost Net.
    - Plan Cost Net ↓ \$28k (-33.2%) to current \$57k.
    - Plan Cost Net PMPM ↓ \$.73 (-46.3%) to current \$.84.
    - Patient Count ↓ 30 to current count of 55.
    - Adjusted Rxs ↓ 82 to current count of 184.
- **Cancer:** Previous ranked 5<sup>th</sup>, currently ranked 3<sup>rd</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$270k (88.0%) to current \$577k.
  - Plan Cost Net PMPM ↑ \$2.87 (51.2%) to current \$8.47.
  - Patient Count ↑ 32 to current count of 140.
  - Adjusted Rxs ↑ 97 to current count of 412.
- **Notable Drug Changes within Indication:**
  - **Verzenio:**
    - Previous ranked 3<sup>rd</sup>, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net ↑ \$65k (151.2%) to current \$108k.
    - Plan Cost Net PMPM ↑ \$.80 (102.0%) to current \$1.58.
    - Patient Count ↑ 1 to current count of 3.
    - Adjusted Rxs ↑ 5 to current count of 10.
  - **Venclexta:**
    - New, currently ranked 2<sup>nd</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$61k.
    - Plan Cost Net PMPM: New, current \$.89.
    - Patient Count: New, current count of 2.
    - Adjusted Rxs: New, current count of 6.



- **Lynparza:**
  - New, currently ranked 4<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net: New, current \$50k.
  - Plan Cost Net PMPM: New, current \$.73.
  - Patient Count: New, current count of 1.
  - Adjusted Rxs: New, current count of 6.
  
- **Viral Infections:** Previous ranked 62<sup>nd</sup>, currently ranked 9<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↑ \$250k (12,702.1%) to current \$252k.
  - Plan Cost Net PMPM ↑ \$3.67 (10,192.1%) to current \$3.70.
  - Patient Count ↑ 207 to current count of 616.
  - Adjusted Rxs ↑ 303 to current count of 950.
  
- **Notable Drug Changes within Indication:**
  - **Paxlovid:**
    - New, currently ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net: New, current \$243k.
    - Plan Cost Net PMPM: New, current \$3.56.
    - Patient Count: New, current count of 207.
    - Adjusted Rxs: New, current count of 196.
  
  - **Other drug changes in this indication were not notable.**
  
- **Ophthalmic Conditions:** Previous ranked 6<sup>th</sup>, currently ranked 24<sup>th</sup> by Plan Cost Net.
  - Plan Cost Net ↓ \$236k (-78.6%) to current \$64k.
  - Plan Cost Net PMPM ↓ \$4.53 (-82.8%) to current \$.94.
  - Patient Count ↑ 30 to current count of 140.
  - Adjusted Rxs ↑ 42 to current count of 274.
  
- **Notable Drug Changes within Indication:**
  - **Tepezza:**
    - No current utilization, previously ranked 1<sup>st</sup> by Plan Cost Net.
    - Plan Cost Net: Previously \$247k.
    - Plan Cost Net PMPM: Previously \$4.51.
    - Patient Count: Previous count of 1.
    - Adjusted Rxs: Previous count of 4.
  
  - **Other drug changes in this indication were not notable.**

**Peer Comparison:**

- Government – West Region/SaveOn (custom peer created for PEBP PPO plan)
- PEBP PPO is outperforming the peer.
- PEBP PPO experienced Plan Cost Net PMPM of \$102.23 compared to peer of \$126.34.
- PEBP PPO Peer experienced Trend of 15.4%, compared to the Peer of 24.1%.

Total Overall Trend		% Change
<b>Current Period - Plan Cost Net PMPM</b>	<b>\$96.21</b>	
Utilization	\$4.32	5.1%
Unit Cost	\$8.12	9.7%
Member Share	(\$0.40)	(0.5%)
<b>Total Change in Plan Cost Net PMPM</b>	<b>\$12.04</b>	<b>14.3%</b>
<b>Previous Period - Plan Cost Net PMPM</b>	<b>\$84.17</b>	

**Summary of Total** – Overall the main driver of Trend was Non-Specialty Unit Cost. This was primarily driven by the indications of vaccinations and diabetes. For the indication of vaccinations this is due to Covid vaccines no longer having a \$0 ingredient cost. For the indication of diabetes this is due to a shift to higher costing GLP-1 drugs.

Trend was mitigated by increased rebates of 24.9%. This produced a negative Unit Cost Trend of (-3.2%) on Specialty drugs and reduced overall Unit Cost Trend to 9.7%. However, Specialty experienced an 8.5% increase in utilization cost. This was driven by a 15.9% increase in Specialty patients (113 new patients), which resulted in a 13.7% increase in Specialty days of therapy.

Overall Member Cost was mitigating to Trend. However, mitigation was only on Specialty drugs and driven primarily by increased contributions from SaveOnSP.

### Key Statistics:

Nevada PEBP Total			
Description	Q1 FY25	Q1 FY24	Change
Average Members per Month	50,758	48,446	4.8%
Number of Unique patients	26,406	24,642	7.2%
Members Utilizing the Benefit	52.0%	50.9%	1.2
Gross Cost/Adjusted Rx	\$150.72	\$137.00	10.0%
Plan Spend	\$24,211,827	\$19,889,344	21.7%
Rebates (estimated)	\$9,560,982	\$7,655,764	24.9%
Plan Cost Net	\$14,650,845	\$12,233,580	19.8%
<b>Plan Cost Net PMPM</b>	<b>\$96.21</b>	<b>\$84.17</b>	<b>14.3%</b>
Non-Specialty Plan Cost Net PMPM	\$77.09	\$62.21	23.9%
Specialty Plan Cost Net PMPM	\$81.91	\$74.63	9.7%
Generic Fill Rate	86.1%	86.5%	-0.4
90 Day Utilization	59.9%	61.3%	-1.4
Retail - Maintenance 90 Utilization	29.5%	28.4%	0.1
Home Delivery Utilization	30.4%	32.9%	-2.4
Member Cost Net %	18.5%	18.5%	0.0

END OF REPORT